Neuphoria Therapeutics’ (NEUP) Neutral Rating Reaffirmed at HC Wainwright

Neuphoria Therapeutics (NASDAQ:NEUP)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports.

NEUP has been the subject of several other research reports. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Neuphoria Therapeutics has an average rating of “Hold” and an average target price of $21.00.

Neuphoria Therapeutics Price Performance

NASDAQ NEUP traded down $0.33 on Friday, hitting $4.76. The company had a trading volume of 50,005 shares, compared to its average volume of 44,659. The company has a market capitalization of $25.66 million, a PE ratio of -1.09 and a beta of 0.72. The company’s fifty day moving average price is $4.72 and its 200-day moving average price is $4.38. Neuphoria Therapeutics has a 12-month low of $3.64 and a 12-month high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.47. On average, sell-side analysts anticipate that Neuphoria Therapeutics will post -4.07 EPS for the current year.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of large investors have recently modified their holdings of NEUP. AdvisorShares Investments LLC grew its holdings in shares of Neuphoria Therapeutics by 129.1% during the fourth quarter. AdvisorShares Investments LLC now owns 134,194 shares of the company’s stock worth $521,000 after buying an additional 75,631 shares in the last quarter. Ikarian Capital LLC purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth $184,000. ADAR1 Capital Management LLC purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth $116,000. Diadema Partners LP grew its holdings in shares of Neuphoria Therapeutics by 133.1% during the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after buying an additional 28,548 shares in the last quarter. Finally, FNY Investment Advisers LLC acquired a new position in shares of Neuphoria Therapeutics during the 4th quarter valued at about $102,000. Hedge funds and other institutional investors own 15.90% of the company’s stock.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.